Feature | April 06, 2011

Trial Results Show Positive Performance for Everolimus-Eluting Stent

April 6, 2011 – A pooled analysis of the SPIRIT II, III, IV and COMPARE trials further reinforces the positive clinical performance of an everolimus eluting coronary stent system. As part of the analysis, two-year results on the safety and efficacy of Abbott’s Xience V was compared to Taxus Liberte and Taxus Express2 paclitaxel-eluting coronary stent systems were presented at the American College of Cardiology's (ACC) Scientific Session in New Orleans.

In a presentation given by Dean J. Kereiakes, M.D., medical director of The Christ Hospital Heart and Vascular Center in Cincinnati, Ohio, predictors of artery re-blockage, cardiac death or heart attack were evaluated out to two years in nearly 7,000 patients from the SPIRIT II, III, IV and COMPARE clinical trials.

The data demonstrated that use of Xience V resulted in significantly lower clinical event rates following a stent procedure. In the pooled analysis, it demonstrated a 36 percent reduction in the risk of major adverse cardiac events (MACE) compared to Taxus (7.3 percent for Xience V versus 11.1 percent for Taxus, p-value

"Xience V consistently demonstrated low adverse cardiac event rates in trial after trial," said Kereiakes. "The SPIRIT II, III, IV, and COMPARE pooled analysis suggests that Xience V reduced the occurrence of adverse events compared to patients treated with the Taxus stent. The low event rates demonstrated by Xience V in these trials are especially impressive given the complexity of patients in the SPIRIT IV and COMPARE trials and confirm that the results seen with Xience V in earlier randomized clinical trials are consistent with clinical practice."

In addition to the 36 percent reduction in the risk of overall MACE, data also were presented at ACC from the pooled analysis that demonstrated the following for Xience V:

• A 47 percent reduction in the risk of heart attack (2.9 percent for Xience V versus 5.5 percent for Taxus, p-value

• A 40 percent reduction in the risk of cardiac death or heart attack (4.0 percent for Xience V versus 6.6 percent for Taxus, p-value

• A 36 percent reduction in the risk of ID-TLR (4.1 percent for Xience versus 6.6 percent for Taxus, p-value

• A 70 percent reduction in the risk of stent thrombosis, defined as definite or probable according to ARC (Academic Research Consortium) (0.7 percent for Xience V vs. 2.3 percent for Taxus, p-value

"The pooled analysis of the SPIRIT II, III, IV and COMPARE trials further supports the strong body of clinical evidence that has made Xience V a leading drug eluting stent technology for patients and physicians," said Charles A. Simonton, M.D., FACC, FSCAI, divisional vice president, medical affairs, and chief medical officer, Abbott Vascular. "Xience V's long-term clinical performance is backed by clinical data from more than 30,000 patients worldwide."

The SPIRIT trials were sponsored and conducted by Abbott. SPIRIT IV included 3,690 patients, many of whom presented with multiple medical complexities, including more than 1,100 patients with diabetes, and patients with small vessels, long lesions, and multiple lesions. The COMPARE study was a physician-initiated trial involving 1,800 patients with complex vascular disease. This pooled analysis was performed independently of Abbott. Taxus Liberte was the control in COMPARE and Taxus Express2 was the control in SPIRIT II, SPIRIT III and SPIRIT IV.

For more information: www.abbott.com, www.xiencev.com

Related Content

Synergy stent
Technology | October 05, 2015
October 5, 2015 — The U.S.
News | Heart Failure| October 02, 2015
Cyberonics Inc. announced results from the extension of the ANTHEM-HF clinical study (ENCORE Study). Results of the...
Tryton Side Branch Stent, clinical trial results, Catheterization and Cardiovascular Interventions

Tryton Side Branch Stent image courtesy of Tryton Medical

News | Stents Bifurcation| October 02, 2015
October 2, 2015 — Tryton Medical Inc.
Intact Vascular, TOBA II study, Tack Endovascular System

Image courtesy of Intact Vascular

News | Peripheral Arterial Disease (PAD)| October 01, 2015
Intact Vascular Inc. announced the U.S. Food and Drug Administration has granted conditional approval for a U.S. and...
Johns Hopkins, sticky gel, stem cells, rat hearts, heart attacks

Hydrogel applied to beating rat hearts improves stem cell uptake by the heart muscle and speeds up tissue healing after heart attack. Image courtesy of Johns Hopkins Medicine.

News | Stem Cell Therapies| September 29, 2015
A sticky, protein-rich gel created by Johns Hopkins researchers appears to help stem cells stay on or in rat hearts and...
News | Cath Lab| September 29, 2015
The Innovation Institute announced that Boston Scientific has signed an agreement to become the founding medical device...
Eluvia drug-eluting vascular stent system, 12-month primary patency, Boston Scientific, MAJESTIC trial, CIRSE

Image courtesy of Boston Scientific

News | Stents Peripheral| September 28, 2015
New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific Eluvia drug-eluting...
predicting arrhythmias, mcgill university, alternans patterns
News | EP Lab| September 28, 2015
Researchers have discovered how to predict some cardiac arrhythmias several steps before they even occur. It’s a...
News | Antiplatelet and Anticoagulation Therapies| September 25, 2015
The Icahn School of Medicine at Mount Sinai has launched the international TWILIGHT clinical trial to test the safety...
Medisafe, medication management, mHealth platform, blood pressure study, hypertension, adherence
News | Hypertension| September 25, 2015
Medisafe, an mHealth platform for medication management, announced the results of its blood pressure study, which...
Overlay Init